This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

35/100

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

To determine the degree to which patients with early Alzheimer disease (AD) being evaluated for anti-amyloid antibody therapies (AATs) adhere to optimal brain-health/lifestyle recommendations.

What this study adds

Evidence grade: Low

This study set out to measure how well patients with early Alzheimer's disease being evaluated for anti-amyloid antibody therapies follow brain-health and lifestyle recommendations. No results on adherence or treatment outcomes are reported in the available text.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Riera, K., Gale, S. A., Ghorayeb, G., McFeeley, B. M., & Daffner, K. R. (2025). Degree of Adherence to Brain Health Recommendations in Patients Pursuing Anti-Amyloid Antibody Therapy for Alzheimer’s Disease (S23.003). Neurology. https://doi.org/10.1212/wnl.0000000000210695

Vancouver

Riera K, Gale SA, Ghorayeb G, McFeeley BM, Daffner KR. Degree of Adherence to Brain Health Recommendations in Patients Pursuing Anti-Amyloid Antibody Therapy for Alzheimer’s Disease (S23.003). Neurology. 2025. doi:10.1212/wnl.0000000000210695.

BibTeX

@article{riera2025-d5d70de7,
  author  = {Riera, Kayla and Gale, Seth A. and Ghorayeb, Georges and McFeeley, Brittany M. and Daffner, Kirk R.},
  title   = {{Degree of Adherence to Brain Health Recommendations in Patients Pursuing Anti-Amyloid Antibody Therapy for Alzheimer’s Disease (S23.003)}},
  journal = {Neurology},
  year    = {2025},
  doi     = {10.1212/wnl.0000000000210695},
  url     = {https://doi.org/10.1212/wnl.0000000000210695}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

To determine the degree to which patients with early Alzheimer disease (AD) being evaluated for anti-amyloid antibody therapies (AATs) adhere to optimal brain-health/lifestyle recommendations.

Why it matters

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 35/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Neurology)
Journal's citation record	4 / 4	Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Kirk R. Daffner: h-index 49 (OpenAlex, whole career)
Institution's track record	3 / 3	Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	0 / 2	Behind a paywall — scores zero
Total	35 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also in Treatments

196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →